Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





High-Sensitivity Neutralizing Antibody Test Detects Strength of Individual Immune Response to COVID-19

By LabMedica International staff writers
Posted on 13 Jul 2021
A multi-dimensional immune response test that tracks multiple combinations of antibody responses against several different antigens for COVID-19 has been enhanced to include a high-sensitivity neutralizing antibody diagnostic, which makes it possible to assess the strength of an individual’s immune response to the SARS-CoV-2 virus.

Aditxt, Inc. More...
(Richmond, VA, USA) has made enhancements to its AditxtScore for COVID-19 which now includes virus-specific infection blocking antibodies that assess the strength of an individual’s immune response to SARS-CoV-2. AditxtScore for COVID-19, which was first introduced in August of 2020, differentiates itself from traditional antibody tests by delivering a detailed view of an individual’s immune response to multiple antigens associated with the SARS-CoV-2 virus. This multi-multiplex approach to capturing the full spectrum of biomarkers associated with SARS-CoV-2 delivers a highly detailed snapshot of an individual’s immune response in a single test cycle. With this new enhancement, AditxtScore for COVID-19 now includes the ability to measure neutralizing antibodies, the subset of virus-specific antibodies that block infection by interfering with cell entry of virus particles.

The level of precision in AditxtScore for COVID-19, along with its ability to measure the neutralizing activity of IgG, IgM and IgA isotypes, can provide clinicians with the data they need to understand the strength and quality of each individual’s immune response to COVID-19, whether through exposure and infection or vaccination. Furthermore, it allows identification of individuals who are vulnerable to SARS-CoV-2 infection due to absence of previous exposure to the virus or vaccines, but possibly more importantly, due to an inadequate immune response to vaccination or infection. This information is critical for the millions of immune-compromised patients who may not develop an adequate immune response to vaccination or exposure for multiple reasons, including: immunosuppressive disease, immunosuppressant medications, anti-cancer medications affecting immune function, or the presence of long-term chronic disease that has exhausted the body’s natural immune response capacity.

“Everyone’s immune response is unique to that individual. We have been studying individual immune responses to COVID-19 and COVID-19 vaccination, and we are finding that the immediacy, strength, and duration of antibody responses can vary widely based on a multitude of variables,” said Amro Albanna, Co-founder and Chief Executive Officer of Aditxt. “The addition of this new AditxtScore for COVID-19 captures important data on how effective an individual’s antibodies are for inactivating the virus. We believe that as more people become vaccinated or exposed to the virus, AditxtScore for COVID-19 with neutralizing antibody diagnostics adds that next level of precision, delivering more detailed information of the strength of immune response against the virus.”

Related Links:
Aditxt, Inc.


Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Portable Electronic Pipette
Mini 96
New
Laboratory Software
ArtelWare
New
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: AiPlex VAS for the MosaiQ platform is designed to help reduce time-to-diagnosis for patients with autoimmune vasculitis (Photo courtesy of AliveDx)

Novel Multiplex Assay Supports Diagnosis of Autoimmune Vasculitis

Autoimmune vasculitis and related conditions are difficult to diagnose quickly and accurately, often requiring multiple tests to confirm the presence of specific autoantibodies. Traditional methods can... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.